Suchergebnisse - "Lenalidomide"

PubPharm (3.638)

1

Ixazomib-induced Sweet's syndrome

enthalten in: Leukemia & lymphoma | 2019

von Oka, S. | Ono, K. | Nohgawa, M.

2

A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev)

enthalten in: Clinical lymphoma, myeloma & leukemia | 2019

von Cabanillas, F. | Rivera, N. | Acosta, M. | +4

3

The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)

enthalten in: Annals of hematology | 2019

von Jo, J. | Lee, H. | Kim, K. | +23

4

The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)

enthalten in: Annals of hematology | 2019

von Jo, J. | Lee, H. | Kim, K. | +23

5

The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)

enthalten in: Annals of hematology | 2019

von Jo, J. | Lee, H. | Kim, K. | +23

6

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Franken, M. | Leeneman, B. | Gheorghe, M. | +3

7

Adult Langerhans cell histiocytosis and immunomodulatory drugs:Review and analysis of thirty-four case reports : = Adult Langerhans cell histiocytosis and immunomodulatory drugs:Review and analysis of thirty-four case reports

enthalten in: World Journal of Hematology = 世界血液学杂志(英文版) | 2019-12-20

China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health

von Endri Mauro | Piero Maria Stefani | Filippo Gherlinzoni

8

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

enthalten in: International journal of hematology | 2019

von Izutsu, K. | Minami, Y. | Fukuhara, N. | +12

9

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

enthalten in: International journal of hematology | 2019

von Izutsu, K. | Minami, Y. | Fukuhara, N. | +12

10

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

enthalten in: International journal of hematology | 2019

von Izutsu, K. | Minami, Y. | Fukuhara, N. | +12

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[364]